This was shown in MPN cell lines, primary MPN patient samples, and mouse models of PV and ET treated with the HSP90 inhibitor PU-H71, without degradation of JAK2 in normal tissues or substantial toxicity. Here, JAK2 is linked to essential thrombocythemia.